Navigation Links
Teen dies after complications from abortion pill

Holly Marie Patterson went to a Planned Parenthood clinic two weeks ago to quietly consider ways to handle a life change she wasn't ready for. One week later, the 18-year-old lay dying on an emergency room //table, the victim of complications after she took the abortion pill.

Patterson's death is likely to reignite the debate surrounding RU-486, the pill approved by the Food and Drug Administration two years ago as a way for women to end pregnancies themselves.

Her father is hoping the tragedy will encourage other women considering abortion to seek support, especially from their families.

Holly Patterson, who lived in the San Francisco suburb of Livermore, visited a Planned Parenthood clinic September 10 to take the pill. She followed the prescribed procedure for using RU-486, taking two more pills at home three days later.

After experiencing bleeding and cramps so severe that she was unable to walk, her boyfriend rushed her to the hospital the following evening, where she was given painkillers and sent home. Three nights later, she was back in the hospital. She died the following day.

An autopsy has been scheduled to determine the cause of Holly's death. But Monty Patterson said he learned from an attending physician at the hospital that she had died after a massive infection caused by fragments of the fetus left inside her uterus caused her to go into septic shock. Planned Parenthood also said it is investigating Patterson's death. A spokeswoman for Danco Laboratories, which makes RU-486, estimated that 200,000 women in the United States and more than 1 million worldwide have used the pill since it was invented in France in the 1980s.

Patients who take RU-486 take the first pill under the care of a physician. A second medication called misoprostol, taken three days later, induces labor so the embryo can be expelled. In 5 to 8 percent of cases, surgery is required to stop the patient's bleeding.
'"/>




Page: 1 2

Related medicine news :

1. Thyroid hormone treatment hastens recovery after cardiac surgery
2. Morning after pill effective up to five days after having unprotected sex
3. Liver donors can thrive after transplant
4. Recouping blood flow after a stroke
5. Quality of life after cancer
6. Blood transfusions beneficial after heart attacks
7. Aspirin - a drug after one’s own hear
8. Postpone intercourse after childbirth
9. Vitamins suppress artery injury after transplant
10. Decrease of Hunger Hormone after Obesity Surgery
11. Incontinence after pregnancy
Post Your Comments:
(Date:10/7/2008)...alth-related Questions for Tonight,s,Presidential ...- WebMD, the leading source of,health information,...ial,candidates, proposed health care policies, loc...t the candidates, stance on health insurance, medi... public health issues., The in-depth coverage is ...
(Date:10/7/2008)...PRNewswire-USNewswire/ -- The Ohio Nurses,Associat...ced today its,final round of endorsed candidates f...o Senate:, SD 26 Karen Gillmor (R) Tiffin, Ohio ...(R) Grove City;, HD 28 Connie Pillich (D) Cincinn...These ONA-endorsed candidates for the Ohio General...
(Date:10/7/2008)...wswire-USNewswire/ -- Kristi Yamaguchi, Olympic,Go... the Stars, has been,named chairperson for the 200...gn in an effort to help raise funds in support of ...e and promote lung health., The American Lung Ass...o conquer Tuberculosis. Today, the Lung Associatio...
(Date:10/7/2008)...ar to more expensive whole-leg color ultrasound, ...lthDay News) -- An older, simpler test to look for...osis, or DVT -- is as effective as a newer, more e...searchers found that 2-point ultrasonography of th...trasound -- was as good at detecting DVT as the ne...
Breaking Medicine News(10 mins):Health News:WebMD Highlights Presidential Candidates' Views on Health Care 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 3Health News:Kristi Yamaguchi Chairs American Lung Association Christmas Seals Campaign 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3
...n revive its human organ donation programme in a b...elopments.// Health and Child Welfare Deputy Min... on resuscitating the programme. Because of its in...raft strong legislative laws to guard it from abus...
...US claim to have identified an alternative diet-ba...crease the growth of brain tumours. // The diet id...eyfried and other researchers is KetoCal, a commer...ydrate diet designed to treat epilepsy in children...
...ent is at loggerheads with the pharmaceutical indu...s for generic medicines. // While Thailand argues ...able to its citizens, drug companies maintain that... law and discourages foreign investment. "We were...
...on therapy may aggravate heart disease in patients...ers at Dana-Farber Cancer Institute. // ADT is one.... The study results were based on data from CaPSU...men with prostate cancer. Although the findings ne...
Other Medicine News:Health News:Diet-based Method to Treat Brain Cancer 2Health News:Drug Companies Hit Out at Thai Generic Drug Scheme 2Health News:Benefits of ADT Against Risk of Heart Ailments 2
(Date:10/7/2008)...ented Immunologic Changes Induced by ...nal Data Indicates Potential in Treating Inflammat...ire/ -- Alba Therapeutics Corporation,presented re...merican,College of Gastroenterology (ACG) 2008 Ann...004, the first Phase IIa trial conducted in celiac...
(Date:10/7/2008)... Annual Scientific Meeting -, ORLANDO, Fla., Oct....als, Inc. (formerly Microbia, Inc.) and Forest Lab...presentation of results from a Phase,2b study asse...ients with,irritable bowel syndrome with constipat...nce- daily oral dosing of linaclotide, across a ra...
(Date:10/7/2008)...acebo-Controlled Phase II Study Shows Sta... MOUNTAIN VIEW, California, October 7 /PRNewswire...ature Phase II data from the,therapeutic prostate ...n,obtained as part of the recently entered partner...he US., The results from the Phase II prospective...
(Date:10/7/2008)...Newswire-FirstCall/ --, - 125 Patient, Prospectiv...ws Statistically Significant Improved Overall Surv...e phase II data from the,therapeutic prostate canc...tained as part of the recently entered partnership...S., The results from the Phase II prospective ran...
Breaking Medicine Technology:Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 5Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 1Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 2Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 3Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 4Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 5Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 6Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 7Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 8Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 9Meningitis Shot Available Effective Year Round 4629 1Meningitis Shot Available Effective Year Round 4629 2Meningitis Shot Available Effective Year Round 4629 3Staying sharp in San Diego 4626 1Gentiva 28R 29 Health Services to Present November 7 at CIBC Healthcare Conference in New York 4623 1Gentiva 28R 29 Health Services to Present November 7 at CIBC Healthcare Conference in New York 4623 2Gentiva 28R 29 Health Services to Present November 7 at CIBC Healthcare Conference in New York 4623 3
...7 /PRNewswire-FirstCall/ --,Pharmacyclics, Inc. an... novel histone deacetylase (HDAC) inhibitor and,Br...esentations,will take place at the American Associ...ng being held April 14-18, 2007, at the Los,Angele...e presentations are as follows:, Sunday, Apri...
...t EASL Conference in Barcelona,Spain, VANCOUVER a...Call/ - MIGENIX Inc. , a clinical-stage developer,... top-line results,confirming the previously announ... evidence of clinical benefit, safety and,tolerabi...osidase,inhibitor, celgosivir (MX-3253), in combin...
Other Medicine Technology:Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 2Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 3Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 2New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 3New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 5New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 6New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 7New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 8
Angled 60 degree blades 5.5 mm.
Accurately tests for Nystagmus when rotated at 8-10 rpm. Drums are 10" high by 8" diameter. Light weight drum of professional quality with ball bearings for effortless spin mechanism. For use 24 to 3
Eschenbach's new 2636 series of stand magnifiers delivers the benefits of high power and a large fields of view. Using a unique doublet lens design, the 2636 offers the highest power recatngular lens
This Illuminated Stand Magnifier offers versatility across a number of different applications. Both the lens and the light are adjustable. Simply tilt the lens and small hand held objects can be work
Medicine Products: